112 related articles for article (PubMed ID: 23031595)
1. Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
Yang Y; Voak A; Wilkinson SR; Hu L
Bioorg Med Chem Lett; 2012 Nov; 22(21):6583-6. PubMed ID: 23031595
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
Hu L; Wu X; Han J; Chen L; Vass SO; Browne P; Hall BS; Bot C; Gobalakrishnapillai V; Searle PF; Knox RJ; Wilkinson SR
Bioorg Med Chem Lett; 2011 Jul; 21(13):3986-91. PubMed ID: 21620697
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
4. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
5. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
6. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug.
Huang TL; Bacchi CJ; Kode NR; Zhang Q; Wang G; Yartlet N; Rattendi D; Londono I; Mazumder L; Vanden Eynde JJ; Mayence A; Donkor IO
Int J Antimicrob Agents; 2007 Dec; 30(6):555-61. PubMed ID: 17920820
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
8. Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Chatelain E; Kaiser M; Wilkinson SR; McKenzie C; Ioset JR
J Med Chem; 2012 Jun; 55(11):5554-65. PubMed ID: 22550999
[TBL] [Abstract][Full Text] [Related]
9. Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs.
Hall BS; Meredith EL; Wilkinson SR
Antimicrob Agents Chemother; 2012 Nov; 56(11):5821-30. PubMed ID: 22948871
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
11. An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs.
Voak AA; Gobalakrishnapillai V; Seifert K; Balczo E; Hu L; Hall BS; Wilkinson SR
J Biol Chem; 2013 Oct; 288(40):28466-76. PubMed ID: 23946481
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmaceutical properties of N-acyloxymethyl prodrugs of Allop with potential anti-trypanosomal activity.
Gualdesi MS; Ortiz CS; Raviolo MA
Drug Dev Ind Pharm; 2016; 42(4):602-10. PubMed ID: 26181622
[TBL] [Abstract][Full Text] [Related]
13. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug.
Chung MC; Güido RV; Martinelli TF; Gonçalves MF; Polli MC; Botelho KC; Varanda EA; Colli W; Miranda MT; Ferreira EI
Bioorg Med Chem; 2003 Nov; 11(22):4779-83. PubMed ID: 14556793
[TBL] [Abstract][Full Text] [Related]
15. Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
Çelik A; Yetiş G; Ay M; Güngör T
Bioorg Med Chem Lett; 2016 Aug; 26(16):4057-60. PubMed ID: 27390065
[TBL] [Abstract][Full Text] [Related]
16. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation.
Hall BS; Wilkinson SR
Antimicrob Agents Chemother; 2012 Jan; 56(1):115-23. PubMed ID: 22037852
[TBL] [Abstract][Full Text] [Related]
17. Design of anticancer prodrugs for reductive activation.
Chen Y; Hu L
Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase.
Atwell GJ; Boyd M; Palmer BD; Anderson RF; Pullen SM; Wilson WR; Denny WA
Anticancer Drug Des; 1996 Oct; 11(7):553-67. PubMed ID: 8921936
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of dihydronaphthofurandiones and dihydrofuroquinolinediones with trypanocidal activity and analysis of their stereoelectronic properties.
Tapia RA; Salas C; Morello A; Maya JD; Toro-Labbé A
Bioorg Med Chem; 2004 May; 12(9):2451-8. PubMed ID: 15080940
[TBL] [Abstract][Full Text] [Related]
20. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture.
Li Z; Han J; Jiang Y; Browne P; Knox RJ; Hu L
Bioorg Med Chem; 2003 Sep; 11(19):4171-8. PubMed ID: 12951148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
